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T-cell expression levels of CC chemokine receptor 5 (CCR5) are a
critical determinant of HIV/AIDS susceptibility, and manifest wide
variations (i) between T-cell subsets and among individuals and
(ii) in T-cell activation-induced increases in expression levels. We
demonstrate that a unifying mechanism for this variation is differ-
ences in constitutive and T-cell activation-induced DNA methylation
status of CCR5 cis-regulatory regions (cis-regions). Commencing at
an evolutionarily conserved CpG (CpG −41), CCR5 cis-regions man-
ifest lower vs. higher methylation in T cells with higher vs. lower
CCR5 levels (memory vs. naïve T cells) and in memory T cells with
higher vs. lower CCR5 levels. HIV-related and in vitro induced T-cell
activation is associatedwith demethylation of these cis-regions. CCR5
haplotypes associated with increased vs. decreased gene/surface ex-
pression levels and HIV/AIDS susceptibility magnify vs. dampen
T-cell activation-associated demethylation. Methylation status of
CCR5 intron 2 explains a larger proportion of the variation in CCR5
levels than genotype or T-cell activation. The ancestral, protective
CCR5-HHA haplotype bears a polymorphism at CpG −41 that is
(i) specific to southern Africa, (ii ) abrogates binding of the tran-
scription factor CREB1 to this cis-region, and (iii) exhibits a trend
for overrepresentation in persons with reduced susceptibility to
HIV and disease progression. Genotypes lacking the CCR5-Δ32
mutation but with hypermethylated cis-regions have CCR5 levels
similar to genotypes heterozygous for CCR5-Δ32. In HIV-infected
individuals, CCR5 cis-regions remain demethylated, despite res-
toration of CD4+ counts (≥800 cells per mm3) with antiretroviral
therapy. Thus, methylation content of CCR5 cis-regions is a cen-
tral epigenetic determinant of T-cell CCR5 levels, and possibly
HIV-related outcomes.
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CC chemokine receptor 5 (CCR5) is the major coreceptor forT-cell entry of HIV-1 (1). CCR5 levels on T cells influence
HIV acquisition, disease progression rates, viral load, and im-
mune recovery during antiretroviral therapy (ART), among
other traits (1–4) (discussed in ref. 5). In these instances, lower
CCR5 levels correlate with beneficial outcomes. Polymorphisms
in the ORF and cis-regulatory regions (cis-regions) of CCR5 that
correlate with higher vs. lower surface and/or gene expression
levels are associated with increased vs. decreased HIV/AIDS risk
and immune recovery (4–12). Classic examples are homozygosity
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and heterozygosity of the 32-bp deletion in the CCR5 ORF
(CCR5-Δ32), which are associated with complete and reduced
CCR5 levels, respectively (4, 12).
However, polymorphisms are unlikely to unify the four key
features of T-cell CCR5 expression. (i) CCR5 levels vary widely on
T-cell subsets. The differentiation state of T cells influences CCR5
levels. Expression is higher on memory compared with naïve T cells
(13, 14). Among memory T cells, expression is higher on effector
compared with central memory T cells (13, 14). (ii) There is wide
interindividual variation in CCR5 levels that cannot be fully
explained by polymorphisms. CCR5 levels differ by up to 20-fold on
T cells and, paradoxically, many individuals without CCR5-Δ32
have CCR5 levels similar to CCR5-Δ32 heterozygotes (2, 3, 13).
(iii) CCR5 levels are up-regulated in settings associated with in-
creased T-cell activation (henceforth “activation”), such as HIV in-
fection (15). (iv) The degree of activation-associated up-regulation of
CCR5 varies significantly among individuals (15).
Although separate mechanisms can be invoked, we sought a
unified mechanism for these four features of T-cell expression of
CCR5. We conceptualized that epigenetic features such as DNA
methylation status of cytidine phosphate guanidine (CpG) di-
nucleotides in the cis-regions of CCR5 may serve as a unifying
mechanism. This thesis would be bolstered if the following four
criteria were to be met (models are shown in SI Appendix, Fig. S1).
There is a well-established link between higher DNA methylation
content in cis-regions and lower gene expression (16). Hence,
constitutive inter–T cell-type and interindividual differences in
CCR5 levels may relate to constitutive inter–T cell-type (criterion
1) and interindividual (criterion 2) differences, respectively, in
DNA methylation content of specific CCR5 cis-regions. Addi-
tionally, DNA methylation, in concert with other epigenetic
mechanisms (e.g., histone modifications), interfaces between
environmental/immune signals and gene expression programs
that control T-cell differentiation and effector functions during
inflammation (17). Hence, activation-induced up-regulation of
CCR5 levels may relate to demethylation of CCR5 cis-regions
(criterion 3). Finally, allele-specific methylation influences gene
expression and disease outcomes (18). Hence, the well-docu-
mented association of CCR5 haplotypes with increased vs. de-
creased HIV/AIDS susceptibility may relate to their cis-regions
manifesting greater vs. lower sensitivity, respectively, to activation-
induced demethylation (criterion 4). To test our hypothesis, these
criteria were examined using ex vivo and in vitro approaches and
multiple study populations (SI Appendix, Materials and Methods).
Results
CCR5 cis-Regions Selected for Methylation Analyses. Fig. 1A depicts
the nomenclature and numbering system and the three-exon
gene structure of CCR5; the CCR5 ORF is in exon 3 (6, 19). We
focused on the DNA methylation status of an ∼5.2-kb cis-region
between CCR5 −5177 and +1 (Fig. 1A), because this cis-region is
influential in regulating gene expression.
First, two sets of alternatively spliced CCR5 mRNA isoforms
are derived from two CCR5 promoters (CCR5-Pr2 and CCR5-Pr1)
in this cis-region (Fig. 1A) (6). CCR5-Pr2 drives the production of
“full-length” mRNA isoforms that contain the 5′-most exon 1.
Exon 1-containing CCR5 transcripts are more abundant in T cells
that constitutively express higher compared with lower CCR5 levels
(e.g., memory vs. naïve T cells, respectively) (19). In contrast,
CCR5-Pr1 drives the production of “truncated” transcripts that
lack exon 1; these mRNA isoforms are constitutively expressed in
both naïve and memory T cells (19). Second, regions 5′ ofCCR5-Pr2
and 3′ of CCR5-Pr1 also influenceCCR5 gene expression (6, 19–21).
Third, ChIP-seq (chromatin immunoprecipitation sequencing) for
factors such as CCCTC-binding factor (CTCF), cohesin, Rad21, and
Znf143—all known to influence gene expression through insulator
function and 3D chromatin organization (22)—reveals two sharp
coincident enrichment peaks in this region (Fig. 1B). This cis-region
is also enriched for transcription factors such as CREB1 (cAMP
responsive element binding protein 1) that influence CCR5 regu-
lation (20) (Fig. 1B). Two DNase I hypersensitivity sites (HSs) are
coincident with the CTCF peaks; the other HSs were near CCR5-
Pr2 and CCR5-Pr1 (Fig. 1B). The HS in CCR5-Pr2 is more prom-
inent in Th1 cells, which have higher CCR5 levels than Th2 cells
(23) (Fig. 1B), substantiating the idea that a transcriptionally active
CCR5-Pr2 may correlate with higher CCR5 levels on T cells.
Inter–T Cell-Type Differences in DNA Methylation Patterns. To test
for criterion 1, we determined the methylation content of 48
CpGs in this ∼5.2-kb cis-region by bisulfite genomic sequencing
of overlapping gene segments and pyrosequencing of represen-
tative CpGs in the upstream (CpGs −41 to −37), CCR5-Pr2
(CpGs −31 to −28), and intron 2 (CpGs −6 to −2) cis-regions
(Fig. 1C and SI Appendix, Table S1). Because of polymorphisms,
some CCR5 haplotypes have additional CpGs (SI Appendix,
Table S1). We compared the methylation content of CD45RO−
vs. CD45RO+, or CD45RA+ vs. CD45RA− T cells derived from
Fig. 1. CCR5 gene, mRNA structure, and transcriptional and DNA methyl-
ation landmarks. (A) Three-exon CCR5 gene structure, two promoters, and
exon 1-containing (full-length) vs. -lacking (truncated) mRNA isoforms (6).
The upstream region starts ∼4.2 kb upstream of the ORF and indicates where
increased micrococcal nuclease (Mnase) accessibility is apparent in memory
cells compared with naïve cells (6). (B) Wiggle plots depict colocalization of
CTCF, cohesin component Rad21, Znf143, and the transcription factor CREB1
(by ChIP-seq in GM12878 lymphoblastoid cells) and DNase I hypersensitivity
sites in primary CD4+ and CD8+ T cells and Th1 and Th2 cells; derived from
publicly available data. (C) CpG sites examined.
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HIV-negative donors before and after accounting for whether
the sorted T-cell subsets did vs. did not express CCR5 (CCR5+
vs. CCR5−), CD45RO−, or CD45RA+, and CD45RO+ and
CD45RA− are surface markers representative of naïve and
memory T cells, respectively; CCR5+ CD45RO− and CCR5+
CD45RA+ T cells are markers representative of terminally
differentiated effector memory T cells (TEMRA) (24).
In CD45RO− T cells, CpGs −1 to −31 were mostly methylated,
except for those near CCR5-Pr1 (Fig. 2A). In contrast, in
CD45RO+ T cells, these CpGs were extensively hypomethylated,
except in intron 2 (Fig. 2B). CpGs in the CCR5-Pr1 core region
(−17 to −14) were constitutively hypomethylated in CD45RO+
and CD45RO− T cells (Fig. 2 A and B), suggesting that this
epigenetic feature may underlie the constitutive production of
exon 1-containing, CCR5-Pr1–driven mRNAs in T cells. Two
observations substantiate this idea. (i) The Jurkat T-cell line lacks
surface CCR5 expression and transcribes only exon 1-lacking
CCR5 mRNA (13, 19) and, except for CpGs in the core region of
CCR5-Pr1, the remaining cis-regions are heavily methylated (SI Ap-
pendix, Fig. S2A, Left). This methylation pattern agrees with the re-
port by Wierda et al. (25). (ii) In contrast, oral epithelial cells express
very low CCR5 mRNA and surface levels, and the CpGs in the core
of CCR5-Pr1 in these cells are heavily methylated (Fig. 2C).
The methylation content of CpGs −31 to −1 was consistently
lower in CCR5+ compared with CCR5− CD45RO− or CD45RO+
T cells (Fig. 2 D–I). However, in support of criterion 1, CCR5+ and
CCR5− T-cell subsets exhibited a specific spatial distribution of
methylation content in this cis-region (Fig. 2 E–I) and in T cells that
naturally express higher vs. lower CCR5 (e.g., effector vs. central
memory T cells; Fig. 2J). This distribution pattern is summarized in
Fig. 2K. The methylation content of CCR5-Pr2 differentiated
CCR5-expressing vs. -lacking CD45RO− T cells (Fig. 2 E, H, and
K), whereas the methylation content of intron 2 differentiated
CCR5-expressing vs. -lacking CD45RO+ or CD45RO− T cells
(Fig. 2 G, I, and K). Differences in methylation content between
T-cell subsets is also observed in publicly available genome-wide
DNA methylation datasets; however, T cells were not sorted by
CCR5 expression in these studies (SI Appendix, Fig. S2 B and C).
CpG −41 Demarcates Methylation Content. An abrupt transition in
methylation status was observed at CpG −41. In CD45RO+ and
CD45RO− T cells, CpGs upstream of CpG −41 (−48 to −42) were
highly methylated, regardless of CCR5 expression (Fig. 3 A and B).
In contrast, CpGs −41 to −30 showed striking differences by the
differentiation state of the T cell: extensive hypomethylation in
CCR5− or CCR5+ CD45RO+ T cells vs. heavy or moderate
methylation in CCR5− and CCR5+ CD45RO− T cells. Methyl-
ation levels also differed by CCR5 expression levels. Although the
CpGs downstream of CpG −41 were hypomethylated to a greater
extent in CCR5+ compared with CCR5− CD45RO+ or CD45RO−
T cells, the degree of hypomethylation was greater in T cells with
higher compared with lower CCR5 surface levels (Fig. 3 A–D). Also,
the length of the demethylation window in CCR5+CD45RO−T cells
correlated with CCR5 surface levels in the three donors (Fig. 3 A and
D). CpG −41 is evolutionarily conserved in most nonhuman primates
(Fig. 3E), and is in close proximity (∼120 bp) to the signals for CTCF
and its interacting partners and DNase I HSs (Fig. 1 B and C).
Methylation Levels, a Correlate of Interindividual Differences in CCR5
Expression. In support of criterion 2, sorted T cells with pro-
gressively higher CCR5 levels had incrementally lower methylation
content in CCR5 cis-regions (Fig. 4 A and B). This inverse re-
lationship was nonlinear; after reaching a threshold (mean fluo-
rescence intensity of ∼1,000), small reductions in methylation were
associated with exponentially higher CCR5 expression (Fig. 4B).
However, methylation status was relatively similar in T cells sorted
according to whether the levels of the activation marker HLA-DR
were high vs. low (Fig. 4C), suggesting that the methylation status
Fig. 2. Distribution of DNA methylation content in CCR5-Pr2, -Pr1, and -intron 2 in T-cell subsets. (A–G) Methylation content of the indicated CpGs derived by
bisulfite genomic sequencing (BGS) in (A) CD3+CD4+CD45RO− T cells; (B) CD3+CD4+CD45RO+ T cells; (C) oral epithelial cells; and (D–G) CCR5− or CCR5+
CD3+CD45RO− and CD3+CD45RO+ T cells. Each column represents the CpG site interrogated, and each row represents a single clone. Closed and open circles
represent methylated and unmethylated CpG sites, respectively. The asterisks indicate a haplotype-specific polymorphism; CpG −4 is disrupted in one allele
due to a private polymorphism in the donor shown in A and B. Pie charts, % methylation; CpGs −18 and −13 (blue) encompass a core of constitutively
demethylated CpGs within CCR5-Pr1 in T cells. (H–J) Methylation content assessed by pyrosequencing of four representative CpGs located within (H) CCR5-Pr2
(CpG −31 to −28) and (I) intron 2 (CpG −5 to −2) in cell-sorted CCR5+ and CCR5− CD3+ T cells and (J) central memory (TCM; CD45RA−CD45RO+CCR7+) and
effector memory (TEM; CD45RA−CD45RO+CCR7−) T cells. The pyrosequencing data are depicted as mean percentage methylation and error bars depict the
standard error of the mean (SEM). Data are from three donors. **P < 0.01 and *P < 0.05, small vs. larger Δ, relative difference in methylation content.
(K) Schema depicting the relative methylation content of CCR5-Pr2 and CCR5-intron 2 in cell-sorted CCR5-positive and CCR5-negative CD45RO+ and CD45RO− T cells,
supporting criterion 1.
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of CCR5 cis-regions more closely correlated with CCR5 expression
than levels of activation. To substantiate this idea, we investigated
methylation status in CD4+ memory T cells obtained from healthy
blood donors before and after sorting according to HLA-DR status
(negative vs. positive). Irrespective of HLA-DR status, methylation
levels were lower in CD4+ memory T cells that constitutively
expressed higher compared with lower CCR5 levels (Fig. 4D
and SI Appendix, Fig. S3A). Further confirming that methyl-
ation status is a strong correlate for surface levels, in healthy
donors who constitutively expressed lower vs. higher CCR5 on
CD45RA+ (TEMRA) or CD45RO+, T cells had higher vs.
lower methylation levels (SI Appendix, Fig. S3 B–D). The as-
sociation of higher vs. lower methylation status with lower vs.
higher expression of CCR5 mRNA and surface expression is
shown in SI Appendix, Fig. S3 E–G.
T-Cell Activation Induces Demethylation of CCR5 cis-Regions. To test
criterion 3, we used an in vitro activation model in which naïve T
cells were activated with anti-CD3 and anti-CD28 antibodies for
72 h and then cultured for an additional 48 h in the absence of
antibodies (Fig. 5A, model 1); this activation protocol is associated
with an increase in Pr2-driven full-length transcripts and CCR5 ex-
pression (19). In a separate model, naïve T cells were activated and
concurrently placed under conditions that favored their polarization
toward Th1 cells (Fig. 5A, model 2), which is associated with higher
expression of IFN-γ (interferon gamma) and CCR5 (23). T-cell ac-
tivation models 1 and 2 were associated with a decrease in methyl-
ation levels in CCR5 and IFNG (Fig. 5 B and C) and a concomitant
increase in CCR5 and IFNG mRNA expression (Fig. 5 D and E).
Relationship Between Demethylation and Gene Expression.We used
5-aza-2′-deoxycytidine (5-azadC)–induced demethylation and the
Jurkat T-cell line as experimental systems to probe the relationship
between demethylation of CCR5 cis-regions and up-regulation of
CCR5 gene expression. Our rationale was twofold: First, chemi-
cally induced demethylation with 5-azadC has been used to es-
tablish relationships between methylation and gene expression
[e.g., for Foxp3 (26) and Pdcd1 (27)] and, second, Jurkat T cells do
not constitutively express CCR5 protein (13) or the Pr2-driven,
exon 1-containing transcripts that are a correlate of CCR5 on T
cells (19). Increasing concentrations of 5-azadC were associated
with a stepwise decrease in methylation levels in CCR5 cis-regions
(Fig. 5F and SI Appendix, Fig. S2A, Right). This was associated with
a progressive increase in total and exon 1-containing CCR5 tran-
scripts (Fig. 5 G and H) but not of CD4 transcripts (Fig. 5I).
5-AzadC also induced expression of CCR5 protein in Jurkat cells
(Fig. 5J and SI Appendix, Fig. S4).
To determine whether activation and 5-azadC had additive ef-
fects, we stimulated peripheral blood mononuclear cells (PBMCs)
with anti-CD3/CD28 antibodies in the presence or absence of
5-azadC (Fig. 5K). Activation induced demethylation of CCR5 cis-
regions (red vs. blue plots; Fig. 5K), but this effect was accentuated
in the presence of 5-azadC (green vs. red plots; Fig. 5K), aug-
menting CCR5 surface expression (Fig. 5L).
Activation, Methylation, and CCR5 Levels. The above-mentioned
data highlighted an intricate relationship among activation,
CCR5 DNA methylation, and CCR5 surface levels (Fig. 5M).
Using T-cell activation model 1 shown in Fig. 5A, we further
analyzed this relationship in vitro (n > 20 blood donors). The
extent of T-cell activation (categorized as activationhigh vs.
activationlow) and changes in CCR5 surface expression levels
(categorized as CCR5high vs. CCR5low) and DNAmethylation levels
in CCR5 cis-regions was classified into four groups (Fig. 6A): (1)
Activationhigh-CCR5high was associated with demethylation in
both CCR5-Pr2 and intron 2 (concordant epigenetic trait); (2)
activationhigh-CCR5low was associated with demethylation in Pr2 but
with increased methylation in intron 2 (a discordant epigenetic
trait, as activationhigh was expected to be associated with deme-
thylation in intron 2); (3) activationlow-CCR5high was associated
with demethylation in both Pr2 and intron 2 (also a discordant
trait, as activationlow was expected to be associated with higher
methylation in CCR5 cis-regions); and (4) activationlow-CCR5low
was associated with minimal changes in Pr2 and intron 2
(a concordant trait).
Fig. 3. Contrasting distribution of methylation content across an evolu-
tionarily conserved CpG site distinguishes CCR5+ vs. CCR5− CD45RO+ or
CD45RO− T cells. (A and B) CpG −41 (indicated in pink) is a transitional
boundary from high to low methylation in the CCR5 locus in the indicated
T-cell subsets. CpGs −41 and −32 demarcate a variable demethylation window
shown in blue in CCR5+CD45RA+CD45RO− T cells, the length of which associates
with CCR5 levels. Data are from three independent donors (denoted as donors
a–c in C and D). P values, by χ2 for comparisons of the methylation content of
CCR5+ vs. CCR5− sorted T cells. Closed and open circles representmethylated and
unmethylated CpG sites, respectively. Absence of circles indicates polymorphisms
or no data available. The asterisks indicate a polymorphism at CpG −33 in se-
lected clones. The pink arrows indicate CpG −41 that marks the transition in
methylation status. (C) Percent methylation (assessed by pyrosequencing) of the
indicated CpG sites in the same T-cell subsets shown in A and B. Δ refers to the
relative differences of methylation levels between CCR5+ vs. CCR5− CD45RA
−CD45RO+ or CD45RA+CD45RO− CD8+ T cells in each of the three cis-regions
examined. (D) Mean fluorescence intensity (MFI) after sorting of CCR5+CD45RA+
CD45RO− CD8+ T cells (same donors as in A–C) and corresponding methylation
levels (assessed by pyrosequencing) at the indicated CpG sites. (E) Multispecies
alignment of CpG sites upstream of exon 1 in CCR5. Chimp, chimpanzee; RM,
rhesus macaque; SM, sooty mangabey. Lines connecting the data points in this
figure are provided for better visualization of the data.
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To determine whether these epigenetic traits existed ex vivo, we
investigated methylation levels in PBMCs of 85 HIV-positive in-
dividuals (mostly European-Americans) receiving ART. These in-
dividuals maintain higher activation despite viral load suppression
(i.e., residual activation) (28). This choice allowed evaluation of the
relationships among activation, CCR5 methylation, and CCR5 ex-
pression without the confounding effects of active viral replication.
Levels of activation and CCR5 were each significantly higher on
Fig. 4. Methylation content of CCR5 cis-regulatory regions as a basis for interindividual differences in CCR5 levels on T cells. (A) Methylation content at the
indicated CpGs in sorted CCR5+CD3+ T cells obtained from four healthy donors with the indicated postsort levels of CCR5 MFI (four gates per donor), assessed
by pyrosequencing of representative sites. Lines connecting the data points are provided for better visualization of the data. (B) Relationship between
methylation status of CCR5 cis-regions (promoter 2 and intron 2) and CCR5 levels (MFI). The line of best fit was determined by fitting the data to a generalized
linear model using the exponential distribution. CCR5 methylation was calculated as average percent methylation in indicated cis-regions from pooled data
from the same donors as in A. (Right) BGS validation of the inverse correlation between CCR5 expression and DNA methylation content of the indicated CpGs
in CCR5-intron 2 derived from CCR5+ T cells with the indicated postsort MFI. (C) HLA-DR+ CD3+ T cells were sorted based on HLA-DR MFI using two arbitrarily
set cell-sorting gates designated as low and high HLA-DR–expressing T cells. The methylation content in the sorted cells was determined by BGS. The numbers
above the BGS data indicate HLA-DR+ MFI in postsorted T-cell fractions. (D) Methylation levels assessed by pyrosequencing of representative CpGs in the
indicated CCR5 cis-regions in CCR5+CD45RO+HLA-DR− CD4+ T cells from three HIV− persons with higher and three persons with lower CCR5 expression (for
results from CCR5+CD45RO+HLA-DR+ CD4+ T cells, see SI Appendix, Fig. S3A). The mean percentage methylation values are shown and the error bars depict
SEM. (E) Model based on criterion 2.
Fig. 5. T-cell activation- and/or 5-azadC–induced demethylation of CCR5 cis-regions. (A) Schema of T-cell activation (TCA) models: in vitro TCA (model 1) and
Th1 polarization of naïve T cells (model 2). Durations of culture periods with or without TCR (T-cell receptor) stimulation are shown. (B and C) Methylation
levels of the indicated cis-regions of (B) CCR5 and (C) CpG sites in IFNG at the indicated time points after in vitro Th1 polarization (Left) or TCA (Right). For
IFNG the average methylation content of the six CpG sites in three independent donors is shown. For CCR5 the CpG sites are the same as those examined in
Fig. 4A. Error bars indicate SD. Letters denote significant P values by paired Student’s t test for the comparison of each time point at which methylation was
assessed relative to the methylation values at baseline (t = 0) and are as follows: for a–j, 0.006, 0.002, 0.009, 0.002, 0.011, 0.093, 0.017, 0.001, 0.002, and 0.029,
respectively; for a′–e′, 0.016, 0.017, 0.014, 0.003, and 0.006, respectively; and for a′′–e′′, 0.001, 0.000, 0.001, <0.0001, and <0.0001, respectively. (D and E) CCR5
and IFNGmRNA expression at the indicated time points post Th1 polarization or TCA. The y axis is the log10-transformed raw gene expression signals obtained
by RNA-seq. Data are representative of one of three experiments. (F) 5-AzadC dose-dependent DNA demethylation of CCR5 cis-regions in the Jurkat T-cell
line. Methylation was assessed by pyrosequencing at the indicated CpG sites in untreated Jurkat cells (closed squares) and treated with 0.02 (open squares),
0.2 (gray triangles), and 0.5 μM 5-azadC (crosses). (G–I) mRNA quantification of (G) total CCR5 mRNA isoforms, (H) CCR5 exon 1-containing transcripts, and (I)
CD4 transcripts, all evaluated by quantitative RT-PCR. Data represent fold increase relative to untreated. The error bars in G represent ± SEM. 18S rRNA levels
were used for normalization. Increasing concentrations of 5-azadC are represented by triangles (doses are indicated in F). (J) Plots represent the densitometric
analysis of CCR5 expression in 5-azadC–treated Jurkat cells. The relative fluorescence intensities were assessed by confocal microscopy (SI Appendix, Fig. S4)
and measured using NIH ImageJ software. Signals were normalized relative to actin. (K) Methylation content of the indicated CCR5 CpGs in PBMCs derived
from one representative HIV− donor before (blue; t = 0 h) and after 120 h of TCA without 5-azadC (red; t = 120 h) and in the presence of 1 μM 5-azadC
(green). (L) CCR5 surface expression (denoted as percent gated cells) after 120 h of TCA in the absence (−) or presence (+) of 1 μM 5-azadC. The data shown are
representative of one of three experiments. (M) Three-way relationship between TCA, CCR5 methylation status, and CCR5 surface levels. ?, up-regulation via
other mechanisms.
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CD8+ compared with CD4+ T cells (P < 0.001; SI Appendix, Fig. S5
A and B). Activation and CCR5 expression on CD4+ and CD8+ T
cells were positively correlated (r = 0.66 and 0.49; SI Appendix, Fig.
S5 C and D). Although higher activation and CCR5 levels were
each associated with lower methylation in CCR5-Pr2 and CCR5-
intron 2, these inverse correlations were stronger for CCR5 levels
than activation (Fig. 6B). This finding suggested that the degree of
demethylation in CCR5 was more closely related to CCR5 levels
than activation. The inverse correlations were also stronger for the
methylation content in CCR5-intron 2 than CCR5-Pr2 (Fig. 6B and
SI Appendix, Table S2, models 1 and 2). Reflecting the higher ex-
pression of CCR5 on CD8+, the latter associations were stronger in
CD8+ vs. CD4+ T cells.
However, CCR5 methylation status was a closer indicator of
CCR5 surface levels rather than activation status (Fig. 4 C and D).
Furthermore, discordant epigenetic traits (2 and 3) were present
(Fig. 6A). Together, these data indicated that the association
of methylation status with CCR5 levels partly depended on
whether the accompanying activation levels were high or low. To
substantiate this possibility ex vivo, we conducted multivariate
analyses using the methylation data from the 85 virally sup-
pressed HIV+ patients. When placed in a single model, lower
methylation in intron 2 but not in CCR5-Pr2 was associated with
higher CCR5 surface levels (P < 0.001 and P = 0.31, respectively;
SI Appendix, Table S2, models 1–3). The associations between
methylation status of intron 2 and CCR5 levels persisted after
controlling for the accompanying levels of T-cell activation and
proportion of naïve T cells (P = 0.001), CCR5 haplotypes in-
cluding the Δ32-bearing allele (P = 0.003), and variables such as
CD4+ counts before ART (P = 0.006; SI Appendix, Table S2,
models 4–6). The associations between CCR5-Pr2 with CCR5
levels were less robust (P = 0.05, P = 0.05, and P = 0.08; SI
Appendix, Table S2, models 4–6). Naïve T cells were included in
the models to mitigate potential confounding of interindividual
differences in the proportions of naïve T cells, because the CCR5
cis-regions of CD45RO− T cells are more methylated compared
with CD45RO+ T cells (Fig. 2 A and B). Similar associations
were detected in CD4+ T cells. However, because of lower
CCR5 levels on CD4+ compared with CD8+ T cells (SI Ap-
pendix, Fig. S5), the associations were statistically weaker.
Mirroring the results of the multivariate models among individuals
with comparable levels of T-cell activation (activationhigh or
activationlow), a higher vs. lower methylation (methylationhigh
vs. methylationlow) content of intron 2 was associated with lower
vs. higher CCR5 levels (Fig. 6C). These findings revealed two
concordant and two discordant activation-epigenetic traits (Fig. 6C
and D). The concordant traits were activationhigh-methylationlow,
which associated with CCR5high, and activationlow-methylationhigh,
which associated with CCR5low. Discordant traits were acti-
vationhigh-methylationhigh, as it was associated with CCR5low,
and activationlow-methylationlow, as it was associated with
CCR5high. Methylation status of CCR5-intron 2 explained 32%
of the variability in CCR5 levels on CD8+ T cells, more than the
explained variability related to activation (∼26%), the proportion
of naïve T cells (∼23%), or possession of CCR5-Δ32 (2%). The
discovery that CCR5-intron 2 and to a lesser extent CCR5-Pr2
predicted such a large proportion of the variability in CCR5 T-cell
levels is consistent with the observation that methylation status of
CCR5-intron 2 discriminates CCR5 expression on memory T cells
to a greater degree than CCR5-Pr2 (Fig. 2 F–I).
Allele-Specific Activation-Induced Demethylation of CCR5. A possible
reason for the above-mentioned discordant epigenetic traits was
polymorphisms in CCR5 cis-regions that amplify vs. dampen the
sensitivity of CCR5 cis-regions for activation-associated demethyl-
ation (criterion 4). To test this idea, we focused mainly on
the ancestral −2459G/−2135T-containing CCR5-HHA haplotype
(most comparable to chimpanzee CCR5) and the −2459A/−2135C-
containing CCR5-HHE haplotype (Fig. 7A) for two reasons.
Foremost, CCR5-HHA and -HHE haplotypes are antipodal with
respect to transcriptional (promoter) strengths (least vs. highest,
respectively), and thus represent evolutionarily nodal genetic
backgrounds upon which additional promoter haplotypes that have
low (e.g., HHC) vs. high (HHG) transcriptional activity arose (Fig.
7A) (6). Also, genotypes containing HHA and HHE haplotypes are
associated with reduced vs. enhanced HIV/AIDS susceptibility,
respectively (4, 5, 7, 10–12).
For ex vivo analyses, we evaluated the 85 HIV+ individuals
maintaining treatment-induced viral suppression (28) to enable
study of activation stimuli (i.e., residual activation) that induce
demethylation of CCR5 cis-regions in the absence of active viral
replication. A substantial proportion of individuals without the
CCR5-Δ32–containing HHG*2 haplotype (Wt/Wt) had CCR5
levels as low as those of CCR5-Δ32 heterozygotes (Fig. 7B,
columns 1 and 2, respectively). A progressive increase in methylation
content [quartile (Q) 1→Q4; i.e., hypermethylation] of intron 2 in
Fig. 6. Interindividual differences in sensitivity of CCR5 cis-regions to HIV- or activation-induced demethylation. (A) In vitro TCR activation-induced demethylation
of CCR5 cis-regions and the relationship to CCR5 levels and T-cell activation. Changes in (Top) CCR5 and HLA-DR expression on CD3+CD4+ T cells and (Bottom) %
methylation of representative CpGs in CCR5-Pr2 and CCR5-intron 2 obtained by pyrosequencing. Changes were assessed in PBMCs from six representative blood
donors stimulated with anti-CD3/CD28 antibodies (19) (the protocol is in Fig. 5A). Data were computed from results at t = 0 h and t = 120 h of the TCA protocol.
(B) Correlation (Pearson’s r) between%methylation of CpGs in CCR5-Pr2 (Left) and CCR5-intron 2 (Right) with% CCR5+, CCR5 MFI, and% CD38+HLA-DR+ CD8+
T cells. Large- and small-sized symbols indicate P < 0.01 and P < 0.05, respectively. Data are from 85 HIV+ individuals from the SCOPE (Observational Study of the
Consequences of the Protease Inhibitor Era) cohort with ART-induced viral load suppression. (C) Box plots depict the CCR5 levels (MFI) on CD8+ T cells according
to whether the activation levels were higher (H) vs. lower (L) than the median TCA in the overall cohort (activation was measured as % CD8+CD38+HLA-DR+ T
cells) and/or whether the methylation levels of CCR5-intron 2 were higher vs. lower thanmedian methylation content in this cis-region in the overall cohort. Data
are from 72 individuals receiving ART (excluded those bearing the Δ32 mutation). P values are indicated between the groups. Horizontal line in the box, median;
ends of the boxes, upper and lower quartiles; red dots in the box, mean; blue dots outside the box, outliers. (D) Model supporting criterion 3.
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Wt/Wt genotypes was associated with progressively lower CCR5
levels (Fig. 7B, columns 3–6). Modest differences in methylation
content (∼8–10% between quartiles) were associated with prom-
inent differences in CCR5 levels (Fig. 7B, columns 3–6). Methyl-
ation quartiles 3 and 4 were associated with CCR5 levels similar to
those of CCR5-Δ32 heterozygotes (Fig. 7B, compare columns 5
and 6 vs. 2). Similarly, among CCR5-Δ32 heterozygotes, higher
methylation status of intron 2 was associated with even lower
CCR5 levels (Fig. 7B, compare column 7 vs. 8).
A progressive increase in methylation in CCR5-intron 2 was
associated with a stepwise decrease in the proportion of Wt/Wt
chromosomes with the HIV disease-accelerating HHE haplotype
(P = 0.002 by Cochran–Amitrage test for trend) and, conversely,
an increase in the proportion of Wt/Wt chromosomes with HIV
disease-retarding haplotypes (e.g., HHA, HHC, and HHF*2)
(4, 5, 7, 10–12) (Fig. 7B, pie slices). The detrimental HHE was
associated with an ∼70% lower likelihood, whereas the pro-
tective CCR5-HHC/HHC genotype (5, 7) was associated with a
3.7-fold higher likelihood of having higher compared with lower
methylation in intron 2 [HHE: odds ratio (OR) = 0.28, 95%
confidence interval (CI) = 0.11–0.74, P = 0.01; CCR5-HHC/
HHC genotype: OR = 3.67, 95% CI = 0.90–14.90, P = 0.06].
These data indicated that T-cell CCR5 levels linked to a CCR5
haplotype pair (genotype) are, in part, related to whether one or
both haplotypes manifest increased (e.g., HHE) vs. reduced (e.g.,
HHA or HHC) sensitivity to activation-associated demethyla-
tion. Congruent with this idea, genotypes containing at least one
HHE compared with those lacking HHE were associated with
higher CCR5 levels (Fig. 7C) and lower intron 2 methylation
content (Fig. 7D). In contrast, HHC/HHC compared with HHC/
HHE haplotype pairs were associated with lower CCR5 levels
(Fig. 7C) and higher intron 2 methylation content (Fig. 7D).
To mitigate confounding effects of the CCR5-Δ32 mutation on
CCR5 levels, in these analyses we excluded individuals (n = 13)
bearing one Δ32-containing HHG*2 haplotype. In our cohort, those
lacking HHE mainly had the CCR5-HHA/HHC or -HHC/HHC
Fig. 7. Associations among HIV/AIDS-modifying polymorphisms in CCR5 with increased vs. decreased sensitivity of CCR5 cis-regions to undergoing HIV- or activation-
associated demethylation. (A) Polymorphisms in the coding regions of CCR5 [wild type (Wt) vs. Δ32] and CCR2 (V64I) and the CCR5 promoter were categorized into
CCR5 human haplogroups (HH) A–G*2 using an evolutionarily based strategy (6). HHF*2 and HHG*2 represent the CCR2-64I– and CCR5-Δ32–containing haplotypes,
respectively. Relative haplotype-specific promoter activity assessed by transcriptional reporter assays is indicated (Bottom) (8). (B) Association between DNAmethylation
(assessed by pyrosequencing of representative CpGs in CCR5-intron 2) and CCR5 levels on CD8+ T cells in 85 HIV+ individuals with stably suppressed viral load (from the
SCOPE cohort). Before accounting for methylation content, CCR5 levels (MFI; ordinate) were assessed in subjects dichotomized as those lacking CCR5-Δ32 (Wt/Wt; n =
72) vs. those possessing a CCR5-Δ32 allele (Wt/Δ32; n = 13).Wt/Δ32 persons had a haploid range of CCR5 expression compared withWt/Wt subjects (columns 1 and 2,
respectively). CCR5 levels inWt/Wt individuals were derived according to the quartiles of the average percent methylation of the representative CpGs in intron 2 (Top;
columns 3–6). CCR5 levels in persons with the Wt/Δ32 genotype were dichotomized according to the median of the overall methylation content in intron 2 in these
individuals (columns 7 and 8; low vs. high). Horizontal black lines indicate the median values of CCR5 MFI in each group. Pie charts show the frequency of the CCR5
haplotypes in individuals withWt/Wt genotype whose methylation content in CCR5-intron 2 classified to the least (column 3) andmost (column 6) methylated quartiles
(Left and Right pie charts, respectively). P values are shown for the differences in CCR5 surface expression according to quartiles of intron 2 methylation in Wt/Wt
subjects (with Q1 as the reference) and high vs. low methylation in CCR5-Δ32 heterozygotes. The error bars represent SEM. (C and D) Mean CCR5 expression (C) and
mean percentagemethylation level of representative CpGs in CCR5-intron 2 (D) in the same individuals (n = 72), categorized by whether they possessed (+) or lacked (−)
at least one CCR5-HHE haplotype and whether they possessed the HHC/HHC vs. HHC/HHE genotypes. The error bars represent SEM. (E) In two healthy donors with the
CCR5-HHA/HHE genotype, HHA-specific and HHE-specific methylation content was determined by bisulfite genomic sequencing after in vitro TCR stimulation (120 h)
with anti-CD3/CD28 Abs. The rs2227010 polymorphism was used to discriminate HHA- vs. HHE-derived clones. (F) Percentage of CD4+ T cells expressing CCR5 in
chimpanzee and HIV− humans. The error bars represent SEM. (G) Genotype frequency of CCR5 −4223C/T (rs553615728) in (i) the Human Genome Diversity Project
(HGDP)-Centre d’Étude du Polymorphisme Humain (CEPH) populations (AF, Africa; C-S-A, Central South Asia; E-A, East Asia; EU, Europeans; M-E, Middle East; OC, Pacific
Ocean) and 80 chimpanzee samples previously studied (44) (Left); (ii) black South Africans from Johannesburg/Soweto (Johan./Soweto) categorized as long-term
nonprogressors (LTNP), HIV controllers (HIC), and progressors (Prog.), as defined in SI Appendix, Materials and Methods (Middle); and (iii) black female sex workers
(FSW) from Durban, KwaZulu-Natal (CAPRISA cohort), South Africa categorized as those who remained HIV-seronegative (≥2 y follow-up; HIV−) vs. those who acquired
HIV during follow-up (HIV+) and a separate cohort of women from the same region who were recruited during primary HIV infection (Right). The differences in
genotype frequency should be compared separately in the study groups from the Johannesburg/Soweto and Durban sites, because geographic differences in SNP
frequency may exist between these two sites. (H) Linkage disequilibrium of −4223T with CCR5-HHA. Data are from persons of African descent shown in G. (I) Model
supporting criterion 4. TF, transcription factor. Red and green triangles represent histone marks. (J) Previously described associations of CCR5 haplotype pairs with CCR5
expression and HIV/AIDS susceptibility. #, inferred from chimpanzee. P values are shown for the compared groups in C–F and H.
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haplotype pairs; these genotypes are associated with lower CCR5
expression, HIV disease retardation, and higher cell-mediated im-
munity (5). These methylation patterns linked to CCR5 genotype
were confirmed in a cohort of 81 therapy-naïve HIV+ women from
Ukraine (SI Appendix, Fig. S6A).
To further confirm that CCR5 haplotypes are associated with dif-
ferential susceptibilities to undergoing activation-induced demethyl-
ation, we evaluated T cells derived from HIV-negative persons with
the CCR5-HHA/HHE haplotype pair after in vitro TCR (T-cell re-
ceptor) stimulation with anti-CD3/CD28 antibodies. This approach
had three advantages. First, it allowed us to evaluate the extent of
activation-induced demethylation of the CCR5-HHA and -HHE
haplotypes concurrently using identical in vitro T-cell activation
conditions. We focused on CCR5-HHA and -HHE because, as
noted above, they are associated with antipodal transcriptional
and clinical outcomes, and HHA is the ancestral haplotype. Second,
this approach mitigated the confounding that occurs when com-
paring persons with the CCR5-HHA/HHA vs. -HHE/HHE haplo-
type pairs, as differences in their immune health could influence
methylation status. Third, this approach controls for racial differ-
ences, as HHA/HHA and HHE/HHE are prevalent mainly in
persons of African vs. European descent (29).
We observed thatCCR5-HHA andCCR5-HHE exhibited reduced
vs. increased permissiveness, respectively, to undergo activation-
induced demethylation in vitro (Fig. 7E). This was also associated
with differential production of HHA (less) and HHE (more) specific
mRNA in heterozygous HHA/HHE donors (SI Appendix, Fig. S6 B
and C). The idea that the ancestral HHA is a correlate of reduced
CCR5 transcription/expression was also highlighted by cross-species
comparisons of CCR5 levels. Chimpanzees are homozygous for
HHA (6), and % CD4+CCR5+ T cells expressing CD4+ cells was
lower in chimpanzees vs. humans (Fig. 7F).
Genotype-dependent differences in responsiveness to activation-
associated demethylation in humans may relate to the finding that
single-nucleotide polymorphisms (SNPs) in CCR5 cis-regions create
or disrupt CpG dinucleotides in a haplotype-specific manner (SI
Appendix, Fig. S7). These haplotype-specific polymorphisms could
potentially alter the binding of several transcription factors, including
those that were previously implicated in CCR5 regulation [e.g.,
C/EBPβ, CREB1, and POU2F2/Oct-2 (19–21)], and thus might
impact CCR5 transcription and its expression (SI Appendix, Fig. S8).
Of note, an SNP designated −4223C/T (rs553615728) (30) dis-
rupts the CpG −41 site (SI Appendix, Fig. S7) and alters the core
consensus motif of a CREB1 binding site (SI Appendix, Fig. S8 A
and B). This SNP is uniquely present in persons from southern
Africa (Fig. 7G, Left), and it occurs on the background of HHA
(Fig. 7H and SI Appendix, Fig. S7). To determine its associations, we
examined blacks from two separate regions of South Africa. In
blacks from Johannesburg/Soweto, the frequency of this SNP was
greater in long-term nonprogressors and HIV controllers compared
with progressors (Fig. 7G, Middle). In black female sex workers
from Durban (31), this SNP was overrepresented in those resisting
HIV infection compared with those who subsequently acquired
HIV infection as well as a separate cohort of women recruited
during primary HIV infection (Fig. 7G, Right). Although suggestive
of a protective effect, these associations did not reach statistical
significance because of the low prevalence of the SNP in the general
population and small sample sizes. Electrophoretic mobility shift
assays (EMSAs) showed reduced binding of CREB1 to the poly-
morphic −4223T compared with wild-type −4223C (SI Appendix,
Fig. S8C). Notably, publicly available ChIP-seq data confirmed cell
type-specific ex vivo CREB1 enrichment in this region (Fig. 1B and
SI Appendix, Fig. S8D).
Collectively, these data support criterion 4 (Fig. 7I). They also
provide an epigenetic mechanism for the reported associations of
CCR5 genotype with HIV acquisition/disease shown in Fig. 7J.
These associations reflect whether the CCR5 genotype contains
one or two haplotypes with CCR5 cis-regions that correlate with
(i) increased (e.g., HHE) vs. reduced (e.g., HHA, HHC) sensi-
tivity to activation-induced demethylation and epigenetic remod-
eling, and (ii) whether the genotype did vs. did not contain the
CCR5-Δ32–containing HHG*2 haplotype (Fig. 7J).
Association of CCR5 DNA Methylation and HIV Disease. HIV-associ-
ated demethylation of CCR5 cis-regions was confirmed in a cohort
with primary HIV infection (Fig. 8A) and two groups of patients
with chronic untreated infection (SI Appendix, Fig. S9A). Suppres-
sion of viral replication by ART during primary infection was as-
sociated with increased methylation (Fig. 8A). Methylation in CCR5
cis-regions was similar in individuals with viral load suppressed by
ART and in spontaneous virologic controllers [i.e., HIV+ in-
dividuals who maintain a low viral load without ART (32)], but the
methylation content in both groups was significantly lower than that
in HIV− persons (Fig. 8A).
When comparing individuals with chronic HIV infection for
whom pre- and posttreatment CD4+ data were available (n = 8),
initiation of ART was associated with decreased CCR5 levels (P =
0.04) and increased methylation content of CCR5-intron 2 (P =
0.02). In paired analyses, changes in methylation status of intron 2
and CCR5 levels were negatively correlated (rho = −0.71, P = 0.04;
Fig. 8B). Previously, we showed that in patients receiving ART,
normalization of CD4+ counts (>800 cells per μL) was associated
with beneficial clinical and immune outcomes (33). In the present
study, among HIV+ patients who received ART during primary
infection, CD4+ ≥800 vs. <800 cells per μL was associated with
higher intron 2 methylation status (Fig. 8A). However, despite
reaching CD4+ normalization, methylation content in intron 2
remained lower than in HIV− persons (Fig. 8A). In the 85 HIV+
patients receiving ART, methylation status of intron 2 was an in-
dependent determinant of CCR5 levels (Fig. 6C and SI Appendix,
Table S2). In these individuals, CCR5 levels and activation had
additive effects on current CD4+ counts (Fig. 8C).
We also examined 29 therapy-naïve HIV+ South African women
with known estimated dates of infection, from whom samples at two
time points post HIV infection were available. Spontaneous (albeit
incomplete) recovery of the methylation status of CCR5 cis-regions
was associated with a lower viral load and higher CD4+ during the
early stages of untreated HIV (Fig. 8 D and E). Representative
examples are shown in SI Appendix, Fig. S9B.
Discussion
Using both in vitro and ex vivo approaches, we demonstrate that
the methylation status of CCR5 cis-regions satisfies the criteria to
serve as a unifying mechanism for the four characteristic features of
CCR5 expression on T cells (SI Appendix, Fig. S1): manifesting
differences among distinct T-cell subsets and individuals as a
mechanism for inter–T cell-type and interindividual differences in
CCR5 expression (criteria 1 and 2); responsiveness to activation as a
mechanism for the positive correlation between activation and
CCR5 levels (criterion 3); and CCR5 genotype-dependent differ-
ences in sensitivity to activation as a mechanism for interindividual
differences in susceptibility to activation- or HIV-associated up-
regulation of CCR5 expression (criterion 4). We therefore propose
that the constitutive and activation-induced DNA methylation sta-
tus of CCR5 cis-regions may contribute substantially to HIV risk
and immune outcomes (SI Appendix, Fig. S1).
Our results indicate that CpG −41 represents an evolutionarily
conserved epigenetic and transcriptional landmark. Downstream
of this CpG site, CCR5 cis-regions manifest a specific hierarchy of
methylation content (highest to least) that depends on both the
differentiation and CCR5 expression status of T cells [i.e., RA+
RO− CCR5− > RA+RO− CCR5+ (TEMRA) ≥ RA−RO+
CCR5− >RA−RO+ CCR5+ T cells]. This hierarchy suggests that
upon activation and differentiation of T cells, DNA demethylation in
the CCR5 cis-region commences close to this site. Further sub-
stantiating this possibility, this CpG site colocalizes within a region
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that exhibits increased nuclease sensitivity (chromatin accessibility) in
memory compared with naïve T cells (19). The hierarchy of meth-
ylation content supports a model of CCR5 gene expression wherein
the balance between the repressive vs. permissive effects of methyl-
ation vs. demethylation on the transcriptional activity/function of
specific CCR5 cis-regulatory regions underlies the (i) differential ac-
tivity of its two promoters in resting vs. activated T cells and (ii)
contrasting expression patterns ofCCR5mRNA isoforms and surface
levels across T-cell subsets (model is shown in SI Appendix, Fig. S10).
Relatively small differences in the methylation content of
CCR5 cis-regions in T cells were associated with a large impact
on CCR5 levels in both HIV− and HIV+ persons. This result is
congruent with the finding from whole-methylome analyses of
PBMCs, showing that up to 13% of differences in methylation
levels differentiates highly expressed vs. silent genes (34). The
observed inverse exponential relationship between methylation
content of specific CCR5 cis-regions and CCR5 levels may rep-
resent the epigenetic corollary to the finding that once a threshold
level of CCR5 on T cells is reached, small increases thereafter
are associated with large increases in HIV infectivity, viral repli-
cation, and AIDS progression rates (35, 36). Conceivably, the
demethylating impact of inflammatory stimuli, for example by
coinfections (e.g., sexually transmitted diseases), may poise the
CCR5 methylation content in T cells at threshold levels, where-
upon exposure to HIV and the ensuing demethylating impact of
HIV may tip the balance toward increased CCR5 levels, promoting
HIV acquisition and/or disease progression.
The methylation status of CCR5-intron 2 closely tracked CCR5
levels on memory T cells, suggesting that its contribution to out-
comes in HIV or other inflammatory diseases could potentially be
substantial. Underscoring this point, (i) the association of CCR5-
intron 2 methylation status with CCR5 levels was independent of
T-cell activation and other covariates; (ii) CCR5 levels of genotypes
bearing a hypermethylated intron 2 were comparable to CCR5
haploinsufficiency imparted by heterozygosity for the CCR5-Δ32
allele; and (iii) the methylation status of CCR5-intron 2 explained a
higher proportion of the variability in CCR5 levels than that
explained by either activation or CCR5 genotype.
Our data suggest that CCR5 haplotypes contain polymorphisms
that by creating or destroying CpG sites may result in cis-regions
that are more susceptible (e.g., HHE) vs. resistant (e.g., HHA,
HHC) to undergoing activation-induced demethylation, despite
comparable levels of activation. Thus, the effects associated with a
CCR5 genotype (e.g., surface levels and HIV/AIDS risk) depend
on both epigenetic and genetic mechanisms. However, epigenetic
mechanisms could have dominant effects, as illustrated by the
associations of HHE: (i) HHE/HHE is consistently associated
with increased CCR5 expression and HIV/AIDS susceptibility,
and (ii) pairing of HHE with HHA, HHC, or HHG*2 is also
associated with adverse clinical outcomes (5, 12).
Our bioinformatics studies suggest that a possible mechanism
for these epihaplotypes is the differential binding of transcription
factors that influence methylation status (37). In proof-of-principle
studies, we focused on the SNP −4223C/T, because it disrupts
the CpG −41 site. This SNP alters the binding of CREB1. This
alteration may have functional consequences, because DNA
methylation levels correlate with sequence-specific binding of
CREB1 to a TCR-responsive intronic enhancer of FoxP3 (38),
and CREB1 plays a key role in the regulation of multiple T cell-
specific genes (39) and CCR5 (20). The overrepresentation of this
SNP in persons with protective HIV phenotypes needs confirma-
tion, but is in general agreement with data suggesting that the
ancestral CCR5-HHA haplotype on which this SNP arises is asso-
ciated with lower CCR5 expression and a protective phenotype in
humans and chimpanzees (5, 7, 11, 12). Our previous work sug-
gested that balancing selection has shaped the pattern of varia-
tion in CCR5 and that HIV-1 resistance afforded by CCR5 5′ cis-
regulatory region haplotypes may be the consequence of adaptive
changes to older pathogens (40). The restriction of the SNP at
CpG −41 to southern Africa, the epicenter of the HIV epidemic,
and its observed associations further substantiate this thesis.
A pathogenic model can be conceptualized wherein upon in-
fection, HIV-associated activation leads to a decline in methyl-
ation levels in CCR5 cis-regions. Thereafter, in therapy-naïve
persons, because of relative susceptibility vs. resistance to the
demethylating impact of HIV-associated activation, methylation sta-
tus either remains low or displays spontaneous recovery, with greater
levels of recovery (hypermethylation) associating positively with lower
viral load and higher CD4+ T-cell counts. However, compared with
HIV-negative individuals, these cis-regions remain in a relatively
demethylated state in HIV+ persons, despite spontaneous or ART-
induced undetectable levels of viral replication and normalization of
CD4+ counts. Several lines of evidence indicate that higher CCR5
levels may directly promote T-cell activation (41–43). Hence, the
Fig. 8. Associations of DNA methylation status in HIV-infected patients. (A) Methylation status of representative CpGs in CCR5-Pr2 and CCR5-intron
2 assessed by pyrosequencing in PBMCs of (i) HIV-seronegative (HIV−) healthy persons; (ii) HIV+ individuals recruited during acute infection in whom
methylation status was evaluated before (pre-ART) and after (post-ART) suppression of viral replication by ART initiated during acute infection; or (iii) elite or
viremic controllers (EC/VC) accrued during acute infection (cohort from ii) or chronic infection in the SCOPE cohort. Significance values are for the following
comparisons: a, pre-ART HIV+ vs. HIV−; b, pre-ART vs. post-ART; c, post-ART with CD4+ ≥800 cells per μL vs. HIV−; and d and e, EC or EC/VC vs. HIV−; a–e were
each P < 0.001. Mean percentage methylation is shown and the error bars represent SEM. (B) Relationship between changes in CCR5 levels on CD8+ T cells and
CCR5-intron 2 methylation content during ART in eight paired HIV+ subjects from SCOPE. (C) Conjoint impact of CCR5 expression and T-cell activation levels
(% CD8+CD38+HLA-DR+ T cells) on current CD4+ T-cell counts in the 85 viral load-suppressed HIV+ subjects from SCOPE. Higher vs. lower activation was
defined by whether values were higher vs. lower than the median. The mean cell counts are shown and the error bars represent standard deviation.
(D) Changes in methylation content in 29 HIV+ therapy-naïve black women from Durban, South Africa (CAPRISA cohort). The net change in % methylation
between two time points during early HIV infection was classified into three groups depending on whether the percent methylation of representative CpG
sites in CCR5-Pr2 and CCR5-intron 2 increased or decreased at least 5%; otherwise they were considered to be “equal.” (E) Correlation (Spearman’s r) between
net change (Δ) in methylation in CCR5-Pr2 and CCR5-intron 2 (i.e., ΔCCR5-Pr2 and ΔCCR5-intron 2; Bottom) observed in two paired samples with net change in
log10 viral load (Bottom; ΔLog10VL) and CD4+ T-cell counts (Top; ΔCD4). Significance values for correlations are indicated.
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higher CCR5 associated with a demethylated CCR5 cis-region in
HIV+ persons, despite suppression of viral load and CD4+ nor-
malization, may serve as a persistent stimulus for low-grade residual
T-cell activation. This may explain why CCR5 blockers are associated
with immunologic benefits unrelated to an antiviral effect (1).
In summary, our findings provide a paradigmatic example by
which epigenetic mechanisms that regulate gene expression (e.g.,
DNA methylation of cis-regulatory regions) may interact with
genetics (e.g., promoter polymorphisms) and environment-induced
host responses (e.g., activation in response to HIV infection) to
affect a trait (i.e., CCR5 surface levels) that influences disease
outcomes (i.e., HIV/AIDS susceptibility). The coupling of activa-
tion with genetically determined differences in activation-induced
demethylation provides a heretofore unrecognized link among
activation and CCR5 epigenetic/genetic traits with HIV/AIDS
susceptibility. Therapeutic exploitation of this link may have clinical
utility. The proclivity of CCR5 cis-regions to undergo demethylation
upon activation may promote the life cycle of HIV and sustain the
HIV epidemic, especially because the CCR5 haplotype (HHE) with
greatest susceptibility for demethylation upon activation, a central
feature of HIV infection, is among the most prevalent CCR5 hap-
lotypes in human populations (29).
Materials and Methods
All studies were approved by the Institutional Review Boards at the
University of Texas Health Science Center at San Antonio and institutions
participating in this study. Detailed methods for cell culture, PBMC isolation,
flow cytometry and cell sorting, Th1 polarization, 5-azadC treatment, and
statistical analyses are provided in SI Appendix,Materials and Methods. CCR5
numbering system is as described previously (6) and the CpG sites examined
are shown in SI Appendix, Table S1. CCR5 polymorphisms were genotyped as
previously described (7). DNA methylation status was assessed by bisulfite
genomic sequencing and also by pyrosequencing assays. Primers and PCR
conditions are listed in SI Appendix, Tables S3 and S4, respectively, and
quality controls are shown in SI Appendix, Fig. S11 and Table S5. Methylation
levels were measured in PBMCs for cohort studies except for subjects from
Ukraine, in whom whole blood was used. We used previously published
methods for conducting antibody mobility shift assays and RT-PCR (6, 19).
Experimental details for RNA-seq are provided in SI Appendix,Materials and
Methods. The sequences of the oligonucleotides used for performing allelic
expression imbalance analysis and EMSA are shown in SI Appendix, Table S3.
Details of motif analysis for transcription factor binding sites are in SI Ap-
pendix, Materials and Methods.
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